

HB3003



98TH GENERAL ASSEMBLY

State of Illinois

2013 and 2014

HB3003

by Rep. Cynthia Soto

SYNOPSIS AS INTRODUCED:

20 ILCS 2310/2310-349 new

Amends the Department of Public Health Powers and Duties Law of the Civil Administrative Code of Illinois. Creates the Childhood Cancer Research Board. Sets forth the membership of the Board. Provides that the Board must review grant applications, make recommendations and comments, and consult with the Department of Public Health in making grants from amounts appropriated from the Childhood Cancer Research Fund to public or private not-for-profit entities for the purpose of conducting childhood cancer research.

LRB098 10952 HLH 41560 b

FISCAL NOTE ACT
MAY APPLY

A BILL FOR

1 AN ACT concerning State government.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Department of Public Health Powers and
5 Duties Law of the Civil Administrative Code of Illinois is
6 amended by adding Section 2310-349 as follows:

7 (20 ILCS 2310/2310-349 new)

8 Sec. 2310-349. The Childhood Cancer Research Board.

9 (a) The Childhood Cancer Research Board is created as an
10 advisory board within the Department. The Board shall consist
11 of 11 members as follows: 2 members appointed by the President
12 of the Senate; one member appointed by the Minority Leader of
13 the Senate; 2 members appointed by the Speaker of the House of
14 Representatives; one member appointed by the Minority Leader of
15 the House of Representatives; 2 members appointed by the
16 Governor, one of whom shall be designated as chair of the Board
17 at the time of appointment; and 2 members appointed by the
18 Director. The Director, or his or her designee, shall serve as
19 an ex officio member of the Board. Members appointed under this
20 Section shall be experts in pediatric cancer or members of the
21 General Assembly; however, no appointing authority may appoint
22 more than one member of the General Assembly to serve during
23 the same term. For the purposes of this Section, an "expert in

1 pediatric cancer" is defined as a physician or scientist who
2 (i) holds a position of leadership in an internationally
3 recognized program of pediatric cancer research at the time of
4 his or her appointment, or (ii) is a fully tenured professor at
5 an institution of higher education. In addition, an expert in
6 pediatric cancer must possess at least one of the following
7 qualifications:

8 (1) a strong track record of publication;

9 (2) participation in a federally-funded pediatric
10 cancer research program;

11 (3) a leadership role in a national cancer research
12 society, including the American Society of Hematology, the
13 American Association of Cancer Research, or the American
14 Society of Clinical Oncology; and

15 (4) participation in a National Cancer Institute or
16 American Cancer Society study section.

17 The Board members shall serve one 2-year term. If a vacancy
18 occurs in the Board membership, the vacancy shall be filled in
19 the same manner as the initial appointment.

20 (b) Board members shall serve without compensation but may
21 be reimbursed for their reasonable travel expenses from funds
22 appropriated for that purpose. The Department shall provide
23 staff and administrative support services to the Board.

24 (c) The Board must review grant applications, make
25 recommendations and comments, and consult with the Department
26 of Public Health in making grants from amounts appropriated

1 from the Childhood Cancer Research Fund to public or private
2 not-for-profit entities for the purpose of conducting
3 childhood cancer research in accordance with Section 6z-93 of
4 the State Finance Act.

5 (d) Grants shall be awarded to research projects that fall
6 within the following categories:

7 (1) understanding the basic biology of specific
8 pediatric cancers using cellular and animal models;

9 (2) pre-clinical studies that translate basic
10 observations into novel diagnostics or therapeutic agents
11 specific to pediatric cancer; or

12 (3) support of Phase I clinical trials of new agents
13 developed at Illinois institutions.

14 (e) The Board shall make its recommendations to the
15 Department no later than March 1 of the year after the
16 application is received.